Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2019.00982
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

A Novel Chromone Derivative With Anti-Inflammatory Property via Inhibition of ROS-Dependent Activation of TRAF6-ASK1-p38 Pathway

PLoS ONE
Multidisciplinary
2012English

Anti-Cancer Effects of JKA97 Are Associated With Its Induction of Cell Apoptosis via a Bax-Dependent and P53-Independent Pathway.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Pristimerin Induces Apoptosis and Autophagy via Activation of ROS/ASK1/JNK Pathway in Human Breast Cancer in Vitro and in Vivo

Cell Death Discovery
Cancer ResearchMolecular NeuroscienceImmunologyCell BiologyCellular
2019English

ROS/Autophagy/Nrf2 Pathway Mediated Low-Dose Radiation Induced Radio-Resistance in Human Lung Adenocarcinoma A549 Cell

International Journal of Biological Sciences
Applied MicrobiologyEvolutionEcologyDevelopmental BiologyCell BiologyMolecular BiologySystematicsBehaviorBiotechnology
2015English

Candidate Pathway-Based Genetic Association Study of Platinum and Platinum–taxane Related Toxicity in a Cohort of Primary Lung Cancer Patients

Journal of the Neurological Sciences
Neurology
2015English

Sophoridine Induces Apoptosis and S Phase Arrest via ROS-dependent JNK and ERK Activation in Human Pancreatic Cancer Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

Oleanolic Acid Induces P53-Dependent Apoptosis via the ERK/JNK/AKT Pathway in Cancer Cell Lines in Prostatic Cancer Xenografts in Mice

Oncotarget
Oncology
2018English

FLLL12 Induces Apoptosis in Lung Cancer Cells Through a P53/P73-Independent but Death Receptor 5-Dependent Pathway

Cancer Letters
Cancer ResearchOncology
2015English

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy